Evidence map›Paper›PMID 31473879›Full record

ArticleNeuromolecular medicine2020

Prolactin is Not Associated with Disability and Clinical Forms in Patients with Multiple Sclerosis.

Wildéa Lice de Carvalho Jennings Pereira, Tamires Flauzino, Daniela Frizon Alfieri, Sayonara Rangel Oliveira, Ana Paula Kallaur, Andrea Name Colado Simão, Marcell Alysson Batisti Lozovoy, Damacio Ramón Kaimen-Maciel, Michael Maes, Edna Maria Vissoci Reiche

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Neuromolecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Wildéa Lice de Carvalho Jennings PereiraLaboratory of Applied Immunology, Health Sciences Center, University of Londrina, Londrina, Paraná, Brazil.
Tamires FlauzinoLaboratory of Applied Immunology, Health Sciences Center, University of Londrina, Londrina, Paraná, Brazil.
Daniela Frizon AlfieriLaboratory of Applied Immunology, Health Sciences Center, University of Londrina, Londrina, Paraná, Brazil.
Sayonara Rangel OliveiraLaboratory of Applied Immunology, Health Sciences Center, University of Londrina, Londrina, Paraná, Brazil.
Ana Paula KallaurLaboratory of Applied Immunology, Health Sciences Center, University of Londrina, Londrina, Paraná, Brazil.
Andrea Name Colado SimãoLaboratory of Applied Immunology, Health Sciences Center, University of Londrina, Londrina, Paraná, Brazil.
Marcell Alysson Batisti LozovoyLaboratory of Applied Immunology, Health Sciences Center, University of Londrina, Londrina, Paraná, Brazil.
Damacio Ramón Kaimen-MacielOutpatient Clinic for Neurology, University Hospital, State University of Londrina, Londrina, Paraná, Brazil.
Michael MaesIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia.
Edna Maria Vissoci ReicheLaboratory of Applied Immunology, Health Sciences Center, University of Londrina, Londrina, Paraná, Brazil. reiche@sercomtel.com.br.ORCID 0000-0001-6507-2839
Universidade Estadual de Londrina · BRDeakin University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An association between prolactinemia with disability, clinical forms, and sex of patients with multiple sclerosis (MS) remains unclear. The aim of this study was to evaluate the association of prolactin with clinical forms and accumulating disability over time in patients with MS. A longitudinal study was carried out with 101 patients with relapsing-remitting MS (RRMS) and 19 with progressive forms of MS (ProgMS). The disability over time, as well as prolactin and ferritin serum levels were evaluated at baseline (T0), 8-month follow-up (T8), and 16-month follow-up. The disability at T0, T8, and T16 was higher among patients with ProgMS than those with RRMS. Prolactin and ferritin levels did not differ over time between both groups. Initially, prolactin was associated with MS disability. After introducing age and sex, the effects of prolactin on disability were no longer significant. Prolactin was associated with age and sex, whereby age was positively associated with disability. In the same way, after introducing age and sex, the effects of diagnosis on prolactin levels, as well as the association between prolactin and ferritin, were no longer significant (P = 0.563 and P = 0.599, respectively). Moreover, 21.6% of the variance in the disability was predicted by age (P < 0.001), and sex (P = 0.049), while prolactin was not significant. In conclusion, the effects of prolactin on the disability and clinical forms of MS patients may be spurious results because those correlations reflect the positive associations of age with the disability and the negative association of age with prolactin.

Indexed as

AdultAgedAge FactorsBiomarkersDisability EvaluationDisease ProgressionFemaleFerritinsFollow-Up StudiesHumansHyperprolactinemiaMaleMiddle AgedMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingProlactinBiomarkersFerritinsProlactinDisabilityFerritinMultiple sclerosisProlactinSpurious result

Identifiers

PMID31473879
OpenAlexW2970815920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.